GLP1R and obesity due to melanocortin 4 receptor deficiency: Supporting this is the general success of novel classes of anti-diabetic drugs leveraging GLP-1 receptor agonists to manage T2DM and obesity in adults and adolescents (Kelly et al., 2020).